Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)...
Pharmaceutical
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations –...
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations –...
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney...
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney...
24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy
DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial...
24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy
DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial...
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in...
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial- 20+ additional clinical sites in...
SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.
COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned...
SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.
COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned...
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE...
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE...
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductionsReporting segment formerly known as...
HopeAI Joins Mayo Clinic Platform to Transform the Future of Drug Development with AI
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug...
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted...
Global Contract Manufacturing Market on Track for $968.7 Billion by 2030
"With rising demand across pharma, electronics, and automotive sectors, contract manufacturing offers cost savings, supply chain stability, and access to...
Canary Speech Appoints Dr. Kang Hsu, Jr. as Chief Medical Officer to Lead Clinical Strategy and Expand Voice Biomarker Adoption
Digital health innovator brings deep clinical informatics and operational leadership to advance Canary Speech's voice-first technology PROVO, Utah, Aug. 12,...